[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUvhtmgcHK9RUyDQpXWuu5rXgVzn9170SmCghE6hIpO4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Democritus University of Thrace",[4],66,false,5,1,9161,4,59,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Presbyopia",20,{"name":18,"count":19},"Cataract",15,{"name":21,"count":22},"Refractive Errors",9,{"name":24,"count":25},"Low Vision",6,{"name":27,"count":25},"Keratoconus",{"name":29,"count":8},"Near Vision",{"name":31,"count":32},"Visual Acuity",3,{"name":34,"count":32},"Vision Disorders",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06630923","PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS","2025-12-01","Human albumin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07581548","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery","2026-12-31","Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,80,105,123,141,167,185,217,235,253,271,289,307,341,365,390],{"intervention":40,"totalTrials":9,"cells":55},{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":76,"NA":78},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":9,"soonestReadout":39},[65],{"nctId":37,"briefTitle":38,"status":66,"phases":67,"primaryCompletion":39,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":75},"RECRUITING",[50],"2026-12-11","2023-01-14",250,[72,73,74],"Diuretics Drug Reactions","Heart Failure; With Decompensation","Albumin; Double",[40],{"trials":77,"activeCount":58},[],{"trials":79,"activeCount":58},[],{"intervention":45,"totalTrials":9,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":92},{"trials":83,"activeCount":58},[],{"trials":85,"activeCount":58},[],{"trials":87,"activeCount":58},[],{"trials":89,"activeCount":58},[],{"trials":91,"activeCount":58},[],{"trials":93,"activeCount":9,"soonestReadout":44},[94],{"nctId":42,"briefTitle":43,"status":95,"phases":96,"primaryCompletion":44,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":102},"NOT_YET_RECRUITING",[],"2027-05-01","2026-05-01",300,[18,101],"Dry Eye",[45,103,104],"Sodium Hyaluronate 0.15% and Trehalose 3% drops","Sodium Hyaluronate 0.2% and Amino acids drops",{"intervention":103,"totalTrials":9,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":108,"activeCount":58},[],{"trials":110,"activeCount":58},[],{"trials":112,"activeCount":58},[],{"trials":114,"activeCount":58},[],{"trials":116,"activeCount":58},[],{"trials":118,"activeCount":9,"soonestReadout":44},[119],{"nctId":42,"briefTitle":43,"status":95,"phases":120,"primaryCompletion":44,"completion":97,"start":98,"enrollment":99,"conditions":121,"interventions":122},[],[18,101],[45,103,104],{"intervention":104,"totalTrials":9,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":135},{"trials":126,"activeCount":58},[],{"trials":128,"activeCount":58},[],{"trials":130,"activeCount":58},[],{"trials":132,"activeCount":58},[],{"trials":134,"activeCount":58},[],{"trials":136,"activeCount":9,"soonestReadout":44},[137],{"nctId":42,"briefTitle":43,"status":95,"phases":138,"primaryCompletion":44,"completion":97,"start":98,"enrollment":99,"conditions":139,"interventions":140},[],[18,101],[45,103,104],{"intervention":142,"totalTrials":9,"cells":143},"Sodium Hyaluronate 0.1% drops",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":145,"activeCount":58},[],{"trials":147,"activeCount":58},[],{"trials":149,"activeCount":58},[],{"trials":151,"activeCount":58},[],{"trials":153,"activeCount":58},[],{"trials":155,"activeCount":58},[156],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT03705949","Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery","COMPLETED",[52],"2018-09-15","2017-09-15",180,[18],[142,166],"Sodium Hyaluronate 0.2% drops",{"intervention":166,"totalTrials":9,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":170,"activeCount":58},[],{"trials":172,"activeCount":58},[],{"trials":174,"activeCount":58},[],{"trials":176,"activeCount":58},[],{"trials":178,"activeCount":58},[],{"trials":180,"activeCount":58},[181],{"nctId":157,"briefTitle":158,"status":159,"phases":182,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":183,"interventions":184},[52],[18],[142,166],{"intervention":186,"totalTrials":9,"cells":187},"Dexamethasone",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":189,"activeCount":58},[],{"trials":191,"activeCount":58},[],{"trials":193,"activeCount":58},[],{"trials":195,"activeCount":58},[],{"trials":197,"activeCount":58},[],{"trials":199,"activeCount":58},[200],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT05279391","Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","UNKNOWN",[52],"2021-11-30","2023-12-31","2020-10-25",150,[210],"COVID-19 Severe Respiratory Failure",[186,212,213,214,215,216],"Low molecular weight heparin","Anakinra 100Mg\u002F0.67Ml Inj Syringe","Tocilizumab","Baricitinib","Dornase Alfa Inhalant Product",{"intervention":212,"totalTrials":9,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":229},{"trials":220,"activeCount":58},[],{"trials":222,"activeCount":58},[],{"trials":224,"activeCount":58},[],{"trials":226,"activeCount":58},[],{"trials":228,"activeCount":58},[],{"trials":230,"activeCount":58},[231],{"nctId":201,"briefTitle":202,"status":203,"phases":232,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":233,"interventions":234},[52],[210],[186,212,213,214,215,216],{"intervention":213,"totalTrials":9,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":238,"activeCount":58},[],{"trials":240,"activeCount":58},[],{"trials":242,"activeCount":58},[],{"trials":244,"activeCount":58},[],{"trials":246,"activeCount":58},[],{"trials":248,"activeCount":58},[249],{"nctId":201,"briefTitle":202,"status":203,"phases":250,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":251,"interventions":252},[52],[210],[186,212,213,214,215,216],{"intervention":214,"totalTrials":9,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":256,"activeCount":58},[],{"trials":258,"activeCount":58},[],{"trials":260,"activeCount":58},[],{"trials":262,"activeCount":58},[],{"trials":264,"activeCount":58},[],{"trials":266,"activeCount":58},[267],{"nctId":201,"briefTitle":202,"status":203,"phases":268,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":269,"interventions":270},[52],[210],[186,212,213,214,215,216],{"intervention":215,"totalTrials":9,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":274,"activeCount":58},[],{"trials":276,"activeCount":58},[],{"trials":278,"activeCount":58},[],{"trials":280,"activeCount":58},[],{"trials":282,"activeCount":58},[],{"trials":284,"activeCount":58},[285],{"nctId":201,"briefTitle":202,"status":203,"phases":286,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":287,"interventions":288},[52],[210],[186,212,213,214,215,216],{"intervention":216,"totalTrials":9,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":292,"activeCount":58},[],{"trials":294,"activeCount":58},[],{"trials":296,"activeCount":58},[],{"trials":298,"activeCount":58},[],{"trials":300,"activeCount":58},[],{"trials":302,"activeCount":58},[303],{"nctId":201,"briefTitle":202,"status":203,"phases":304,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":305,"interventions":306},[52],[210],[186,212,213,214,215,216],{"intervention":308,"totalTrials":9,"cells":309},"Ropivacaine",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":311,"activeCount":58},[],{"trials":313,"activeCount":58},[],{"trials":315,"activeCount":58},[],{"trials":317,"activeCount":58},[],{"trials":319,"activeCount":58},[],{"trials":321,"activeCount":58},[322],{"nctId":323,"briefTitle":324,"status":203,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":340},"NCT04879004","EFFECT - EFFectiveness of ESPB (Erector Spinae Plane Block) in Laparoscopic Cοlectomies Trial",[52],"2022-05-31","2021-01-01",40,[330,331,332,333,308,334,335,336,337,338,339],"Pain, Postoperative","Acute Pain","Postoperative Complications","Pain","Analgesia","Regional Anesthesia","Analgesics","Anesthesia, Local","Colorectal Cancer","Perioperative Pain",[308],{"intervention":342,"totalTrials":9,"cells":343},"Tranexamic Acid",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":345,"activeCount":58},[],{"trials":347,"activeCount":58},[],{"trials":349,"activeCount":58},[],{"trials":351,"activeCount":58},[],{"trials":353,"activeCount":58},[],{"trials":355,"activeCount":58},[356],{"nctId":357,"briefTitle":358,"status":159,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":163,"conditions":362,"interventions":364},"NCT03656445","Tranexamic Acid in Total Knee Replacement",[52],"2017-03-31","2015-10-01",[363],"Osteo Arthritis Knee",[342,342,342],{"intervention":366,"totalTrials":9,"cells":367},"Systane Ultra",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":369,"activeCount":58},[],{"trials":371,"activeCount":58},[],{"trials":373,"activeCount":58},[],{"trials":375,"activeCount":58},[],{"trials":377,"activeCount":58},[],{"trials":379,"activeCount":58},[380],{"nctId":381,"briefTitle":382,"status":159,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":388},"NCT02558218","Postoperative Discomfort and Ocular Redness Following Phacoemulsification Surgery",[52],"2015-05","2015-01",80,[18],[366,389],"tobradex quid",{"intervention":389,"totalTrials":9,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":393,"activeCount":58},[],{"trials":395,"activeCount":58},[],{"trials":397,"activeCount":58},[],{"trials":399,"activeCount":58},[],{"trials":401,"activeCount":58},[],{"trials":403,"activeCount":58},[404],{"nctId":381,"briefTitle":382,"status":159,"phases":405,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":406,"interventions":407},[52],[18],[366,389]]